A Study of GC101 TIL in Advanced Melanoma (BZ)

Clinical trial NCT06120712 · COMPLETED

Trial details

NCT number: NCT06120712
Sponsor: Shanghai Juncell Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Tumor Infiltrating Lymphocytes Safety Melanoma Efficacy Adverse Drug Event

Start date: 2023-11-08
Primary completion: 2024-11-12
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.